HAE Canada is happy to share that Saskatchewan is the latest province to add lanadelumab (TAKHZYRO), a subcutaneous preventative HAE treatment, to their provincial drug formulary. Please click here to read the Exceptional Drug Status (EDS) Benefit Criteria from the provincial government.

This is amazing news for eligible HAE patients living in Saskatchewan. Thank you to both Takeda Canada and the Saskatchewan government for the dedication and work that went into ensuring HAE patients have the option to access this treatment.

To access this treatment, please speak to your HAE specialist or a representative from the OnePath program.